Notably, IL-6 is also associated with chemotherapy resistance and prognosis in lung cancer patients; studies have shown that IL-6 can activate and enhance chemotherapy resistance in lung cancer by activating the ATM/NF-κB pathway (72). This evidence concerns the gene NFKB1 and lung cancer.